Objective To study the clinical features of children with autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A). Methods A retrospective analysis was performed on the medical data of 34 children with GFAP-A who attended the Department of Neurology, Children's Hospital of Chongqing Medical University, from January 2020 to February 2022. The medical data included clinical manifestations, cerebrospinal fluid features, imaging examination results, treatment, and prognosis. Results The median age of onset was 8.4 (range 1.9-14.9) years for the 34 children with GFAP-A. The main clinical manifestations included headache (50%, 17/34), fever (47%, 16/34), visual impairment (47%, 16/34), and disturbance of consciousness (44%, 15/34). Abnormal cerebrospinal fluid results were observed in 19 children (56%, 19/34), among whom 8 children had positive autoantibody. The children with overlap syndrome had significantly higher recurrence rate and rate of use of immunosuppressant than those without overlap syndrome (P<0.05). About 77% (24/31) of the children had good response to immunotherapy, and only 1 child had poor prognosis. Conclusions Children with GFAP-A often have non-specific clinical symptoms and show good response to immunotherapy. Children with overlap syndrome have a high recurrence rate, and early application of immunosuppressants may help to prevent recurrence and alleviate symptoms.
Key words
Autoimmune glial fibrillary acidic protein astrocytopathy /
Glial fibrillary acidic protein /
Encephalitis /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis[J]. JAMA Neurol, 2016, 73(11): 1297-1307. PMID: 27618707. DOI: 10.1001/jamaneurol.2016.2549.
2 Kunchok A, Zekeridou A, McKeon A. Autoimmune glial fibrillary acidic protein astrocytopathy[J]. Curr Opin Neurol, 2019, 32(3): 452-458. PMID: 30724768. PMCID: PMC6522205. DOI: 10.1097/WCO.0000000000000676.
3 Martinez-Hernandez E, Guasp M, García-Serra A, et al. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies[J]. Neurology, 2020, 94(22): e2302-e2310. PMID: 32161029. DOI: 10.1212/WNL.0000000000009239.
4 Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders[J]. Brain, 2019, 142(5): 1310-1323. PMID: 30938427. PMCID: PMC6487334. DOI: 10.1093/brain/awz054.
5 Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. PMID: 26092914. PMCID: PMC4515040. DOI: 10.1212/WNL.0000000000001729.
6 Iorio R, Damato V, Evoli A, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients[J]. J Neurol Neurosurg Psychiatry, 2018, 89(2): 138-146. PMID: 28951498. DOI: 10.1136/jnnp-2017-316583.
7 Fang H, Hu W, Jiang Z, et al. Autoimmune glial fibrillary acidic protein astrocytopathy in children: a retrospective analysis of 35 cases[J]. Front Immunol, 2021, 12: 761354. PMID: 34880859. PMCID: PMC8645641. DOI: 10.3389/fimmu.2021.761354.
8 Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients[J]. Ann Neurol, 2017, 81(2): 298-309. PMID: 28120349. DOI: 10.1002/ana.24881.
9 Yang X, Liang J, Huang Q, et al. Treatment of autoimmune glial fibrillary acidic protein astrocytopathy: follow-up in 7 cases[J]. Neuroimmunomodulation, 2017, 24(2): 113-119. PMID: 28922662. DOI: 10.1159/000479948.
10 Long Y, Liang J, Xu H, et al. Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study[J]. Eur J Neurol, 2018, 25(3): 477-483. PMID: 29193473. DOI: 10.1111/ene.13531.
11 Huang Q, Yang H, Liu T, et al. Patients with suspected benign tumors and glial fibrillary acidic protein autoantibody: an analysis of five cases[J]. Int J Neurosci, 2019, 129(12): 1183-1188. PMID: 31327295. DOI: 10.1080/00207454.2019.1645140.
12 Kimura A, Takekoshi A, Yoshikura N, et al. Clinical characteristics of autoimmune GFAP astrocytopathy[J]. J Neuroimmunol, 2019, 332: 91-98. PMID: 30991306. DOI: 10.1016/j.jneuroim.2019.04.004.
13 Dubey D, Hinson SR, Jolliffe EA, et al. Autoimmune GFAP astrocytopathy: prospective evaluation of 90 patients in 1 year[J]. J Neuroimmunol, 2018, 321: 157-163. PMID: 29793728. DOI: 10.1016/j.jneuroim.2018.04.016.
14 Handoko M, Hong W, Espineli E, et al. Autoimmune glial fibrillary acidic protein astrocytopathy following herpes simplex virus encephalitis in a pediatric patient[J]. Pediatr Neurol, 2019, 98: 85-86. PMID: 31248671. DOI: 10.1016/j.pediatrneurol.2019.05.010.
15 Li J, Xu Y, Ren H, et al. Autoimmune GFAP astrocytopathy after viral encephalitis: a case report[J]. Mult Scler Relat Disord, 2018, 21: 84-87. PMID: 29499442. DOI: 10.1016/j.msard.2018.02.020.
16 Trau SP, Gallentine WB. Autoimmune GFAP-associated meningoencephalomyelitis: a report of a pediatric patient[J]. Pediatr Neurol, 2018, 82: 50. PMID: 29622490. DOI: 10.1016/j.pediatrneurol.2018.02.001.
17 Yang X, Xu H, Ding M, et al. Overlapping autoimmune syndromes in patients with glial fibrillary acidic protein antibodies[J]. Front Neurol, 2018, 9: 251. PMID: 29755396. PMCID: PMC5932346. DOI: 10.3389/fneur.2018.00251.
18 尹燕, 庄霞梅, 李晓明, 等. 自身免疫性胶质纤维酸性蛋白星形细胞病患者头颅磁共振成像特征分析[J]. 中国临床医学影像杂志, 2022, 33(2): 87-90. DOI: 10.12117/jccmi.2022.02.003.
19 徐辉明, 黄清梅, 肖小玉, 等. 自身免疫性胶质纤维酸性蛋白星形细胞病患者脊髓磁共振成像及临床特征分析[J]. 中华神经科杂志, 2019, 52(2): 92-97. DOI: 10.3760/cma.j.issn.1006-7876.2019.02.003.
20 黄莉, 李惠璐, 龙友明, 等. 自身免疫性胶质纤维酸性蛋白星型细胞病的脑电图特点[J]. 实用医学杂志, 2020, 36(19): 2700-2704. DOI: 10.3969/j.issn.1006-5725.2020.19.018.
21 Theroux LM, Goodkin HP, Heinan KC, et al. Extreme Delta brush and distinctive imaging in a pediatric patient with autoimmune GFAP astrocytopathy[J]. Mult Scler Relat Disord, 2018, 26: 121-123. PMID: 30245384. DOI: 10.1016/j.msard.2018.09.015.
PDF(698 KB)
